FRANKLIN LAKES, N.J.,
Jan. 12, 2018 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX) issued the following
statement in response to receiving a warning letter from the U.S.
Food and Drug Administration for its Preanalytical Systems business
unit.
Richard Byrd, worldwide president
of BD Preanalytical Systems said: "Ensuring the safety and quality
of our products is our top priority at BD, and we are dedicated to
maintaining a robust quality system to fulfill this commitment. We
take any potential issue with our products very seriously and are
cooperating fully with FDA on this matter. After the FDA inspection
in July, we took prompt action that we believed fully addressed the
agency's inspectional observations. We are carefully reviewing the
agency's feedback outlined in yesterday's letter with the highest
sense of urgency, and we will provide a full response to FDA on or
before their Feb. 1 deadline. We will
continue to demonstrate our commitment to serving the public health
as well as meeting FDA's expectations."
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help improve patient
outcomes, improve the safety and efficiency of clinicians' care
delivery process, enable laboratory scientists to better diagnose
disease and advance researchers' capabilities to develop the next
generation of diagnostics and therapeutics. BD has a presence in
virtually every country and partners with organizations around the
world to address some of the most challenging global health issues.
By working in close collaboration with customers, BD can help
enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. In 2017, BD welcomed C. R.
Bard and its products into the BD family. For more information on
BD, please visit bd.com.
Contacts:
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
View original
content:http://www.prnewswire.com/news-releases/bd-statement-on-fda-warning-letter-for-preanalytical-systems-business-unit-300581966.html
SOURCE BD (Becton, Dickinson and Company)